Psychiatry and Neurology, Neurology · Riverside, CA
NPI
1639259898
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4646 Brockton Ave Ste 302-2
Riverside, CA, 92506
Phone (951) 742-5255
Groups this clinician bills Medicare through
Medicare paid, 2024
$10K
498 services
Medicare patients, 2024
59
Average age 63
Drug cost, 2024
$2.8M
656 prescriptions
Company payments, 2025
$69.7
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elizabeth H Morrison-Banks was code 99214 (office e&m - established), 52 times for 35 patients. In total Elizabeth H Morrison-Banks billed 498 services in 17 codes, and Medicare paid $10K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 52 | 35 | $101.87 | $5,297 |
| 99223 Hospital E&M - Initial | Facility | 11 | 11 | $137.80 | $1,516 |
By year: 2022 $22K for 26,035 services; 2023 $80K for 13,109 services; 2024 $10K for 498 services.
Medicare prescription drug claims, 2024
In 2024, the drug Elizabeth H Morrison-Banks prescribed most often to Medicare patients was Dalfampridine Er (Dalfampridine), with 100 prescriptions and refills. In total Elizabeth H Morrison-Banks wrote 656 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dalfampridine Er Dalfampridine | 100 | 122 | 12 | $51K |
| Tysabri Natalizumab | 58 | 70 | Under 11 | $465K |
| Copaxone Glatiramer Acetate | 48 | 48 | Under 11 | $292K |
| Baclofen Generic | 30 | 44 | Under 11 | $549 |
| Kesimpta Pen Ofatumumab | 21 | 21 | Under 11 | $172K |
| Gabapentin Generic | 20 | 52 | Under 11 | $816 |
| Ocrevus Ocrelizumab | 20 | 91 | 13 | $758K |
| Mirtazapine Generic | 19 | 19 | Under 11 | $102 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 15 | 23 | Under 11 | $166 |
| Bupropion Xl Bupropion Hcl | 14 | 16 | Under 11 | $198 |
| Pregabalin Generic | 13 | 18 | Under 11 | $129 |
| Teriflunomide Generic | 13 | 13 | Under 11 | $5,724 |
| Ampyra Dalfampridine | 13 | 21 | Under 11 | $82K |
| Aubagio Teriflunomide | 12 | 12 | Under 11 | $112K |
| Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 | 12 | 12 | Under 11 | $281K |
Brand drugs: 243 claims; generic drugs: 413 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elizabeth H Morrison-Banks $69.7 ($69.7 in general payments such as food, travel and fees) from 2 companies. The largest payer was LivaNova USA, Inc. with $55.59.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.